[1] Rustam Al-Shahi Salman, David P Minks, Dipayan Mitra, et al.Effects of antipla-telet therapy on stroke risk by brain imagingfeatures of intracerebral haemorrhage and cerebral small vesseldiseases: subgroup analyses of the RESTART randomised,open-label trial[J]. The Lancet Neurology, 2019, 18(7): 643-652. [2] Rustam Al-Shahi Salman, MS Dennis, PAG Sandercock, et al.Effects of antiplat-elet therapy after stroke due to intracerebralhaemorrhage (RESTART): a randomi-sed, open-label trial[J].The Lancet, 2019, 393(10191): 2613-2623. [3] Donna K. Arnett, Roger S. Blumenthal, Michelle A.Albert, et al.2019ACC/AHA Guideline on the Primary Prevention of Cardio-vascular Disease[J]. Journal of the American College of Cardiology,2019, 74(10): 1376-1414. [4] 李才正,苗佳. 阿司匹林的临床应用进展[J]. 华西医学, 2012,27(7): 988-991. [5] 董怡. 对FDA要求修改非甾体抗炎药说明书的思考[J]. 中国药物警戒, 2005, 2(3): 156-157. [6] 罗兴献, 刘一, 薛学财, 等. 非甾体抗炎药致重症药疹文献汇总分析[J]. 中国医院药学杂志, 2017, 37(21):2155-2159. [7] Settipane RA,Constantine HP, Settipane GA.Aspirin intol-erance and recurrent urticaria in normal adults and children[J].Allergy, 1980, 35(2): 149-154. [8] 谢建翔, 张丽. 重症药疹297 例分析[J]. 中国医院药学杂志,2014, 34(3): 247-249. [9] Lyell A.Toxic epidermal necrolysis (the scalded skin syndrome):a reappraisal[J]. The British journal dermatology,1979, 100(1):69-86. [10] 李飞鸥, 汪芳, 华潞, 等. 阿司匹林致哮喘1例[J]. 中国药物警戒, 2005, 2(2): 93-94. [11] Kowalski M L, Asero R, Bavbek S, et al.Classification and prac-tical approach to the diagnosis and management of hypersensitivityto nonsteroidal anti-inflammatory drugs[J]. Allergy, 2013,68(10): 1219-1232. [12] Lee SY, Nam YH, Koh YI, et al.Phenotypes of Severe CutaneousAdverse R eactions Caused by Nonsteroidal Anti-inflammatoryDrugs[J]. Allergy Asthma Immunol Res, 2019, 11(2): 212-221. [13] Martinez-Cabriales SA, Gomez-Flores M, Ocampocandlani J.News in severe clinical adverse drug reactions: Stevens- Johnsonsyndrome(SJS) and toxic epidermal necrolysis(TEN)[J]. GacetaMedica de Mexico, 2015, 151(6): 777-787. [14] Trautmann A, Akdis M, Schmid-Grendel Meier P, et al.Targetingkeratinocyte apoptosis in the treatment of atopic dermatitis andallergic contact dermatitis[J]. Journal of Allergy Clinical Immunol,2001, 108(5) : 839-846. [15] Mario Sa´nchez-Borges, MD. Clinical management of nonsteroidalanti-inflammatory drug hypersensitivity[J]. Word AllergyOrganization, 2008, 1(2): 29-33. [16] French LE, Trent TJ, Kerdel FA.Use of intravenous immunog-lobulin in toxic epidermal necrolysis and Stevens Johnsonsyndrome: our current understanding[J]. Int Immunopharmacol,2006, 6(4): 543-549. [17] Schneider JA, Cohen PR.Stevens-Johnson syndrome and toxicepidermal necrolysis: A concise review with a comprehensivesummary of therapeutic interventions emphasizing supportivemeasures[J]. Advances in Therapy, 2017, 34(6) : 1-10. [18] Hunger RE, Hunziker T, Buettiker U, et al.Rapid resolution oftoxic epidermal necrolysis with anti-tnf-alpha treatment[J].Journal of Allergy Clinical Immunol, 2005, 116(4) : 923-924. [19] Paquetp, pierard GE. Would cyclosporin a be beneficial to mitigatedrug-induced toxic epidermal necrolysis?[J]. Dermatology, 1999,198(2) : 198-202. [20] Hsu DY, Brieva J, Silverberg NB, et al.Morbidity and mortalityof Stevens- Johnson syndrome and toxic epidermal necrolysis inUnited States adults[J]. Journal of Investigative Dermatology,2016, 136(7): 1387-1397. |